

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05873 A1

- (51) International Patent Classification⁷: C08G 65/329, A61K 9/127
- (21) International Application Number: PCT/US00/18949
- (22) International Filing Date: 12 July 2000 (12.07.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/143,810 14 July 1999 (14.07.1999) US
- (71) Applicant: ALZA CORPORATION [US/US]; 1900 Charleston Road, (P.O. Box 7210), Mountain View, CA 94039-7210 (US).
- (72) Inventor: ZALIPSKY, Samuel; 1202 Truman Street, Redwood City, CA 94061 (US).
- (74) Agents: SIMBOLI, Paul, B. et al.; Alza Corporation, 1900 Charleston Road, P.O. Box 7210, Mountain View, CA 94039-7210 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— With international search report.
— Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
- (54) Title: NEUTRAL LIPOPOLYMER AND LIPOSOMAL COMPOSITIONS CONTAINING SAME



(57) Abstract: Liposomes containing PEG-substituted neutral lipopolymers provide similar circulation times to liposomes incorporating conventional, negatively charged PEG-substituted phospholipids. Use of the uncharged lipopolymers can also present advantages in terms of interactions with cell surfaces and reduced leakage of charged substances, particularly cationic drugs, from the liposomes. The lipopolymers are of formula (I) wherein each of R¹ and R² is an alkyl or alkenyl chain having between about 8 to about 24 carbon atoms, n is about 10 to about 300, Z is selected from the group consisting of hydroxy, alkoxy, benzyloxy, carboxylic ester, sulfonic ester, alkyl or aryl carbonate, amino, and alkylamino, and the linkage L is selected from the group consisting of (i) -X-(C=O)-Y-CH₂-, (ii) -X-(C=O)-, and (iii) -X-CH₂-, wherein X and Y are independently selected from oxygen, NH, and a direct linkage.

NEUTRAL LIPOPOLYMER AND LIPOSOMAL COMPOSITIONS
CONTAINING SAME

Field of the Invention

5 The present invention relates to PEG-substituted neutral lipopolymers and their use in extended circulating time liposomes. Liposomes containing these lipopolymers provide similar blood circulation times when compared with liposomes incorporating conventional, negatively charged PEG-substituted phospholipids.

Cross-Reference to Related Applications

10 The complete disclosure set forth in the U.S. provisional patent application entitled "Neutral Lipopolymer and Liposomal Compositions Containing Same," Serial No. 60/143,810, filed with the United States Patent and Trademark Office on July 14, 1999, is incorporated herein. The applications are commonly owned.

Background of the Invention

15 Liposomes are used for a variety of therapeutic purposes, and in particular, for carrying therapeutic agents to target cells by systemic administration of liposomal formulations of these agents. Advantageously, liposome-drug formulations offer the potential of improved drug-delivery properties, which include, for example,
20 controlled drug release. An extended circulation time is often needed for liposomes to reach a target region, cell or site. In particular, this is necessary where the target region, cell or site is not located near the site of injection. For example, when liposomes are administered systemically, it is desirable to coat the liposomes with a
25 hydrophilic agent, for example, a coating of hydrophilic polymer chains such as polyethylene glycol, (PEG) to extend the blood circulation lifetime of the liposomes. Such surface-modified liposomes are commonly referred to as "long circulating" or "sterically stabilized" liposomes.

30 The most common surface modification to a liposome is the attachment of PEG chains, typically having a molecular weight from about 1000 daltons (Da) to about


5000 Da, and to about 5 mole percent (%) of the lipids making up the liposomes (see, for example, Stealth Liposomes, CRC Press, Lasic, D. and Martin, F., eds., Boca Raton, FL, (1995)), and the cited references therein. The pharmacokinetics exhibited by such liposomes are characterized by a dose-independent reduction in uptake of liposomes by the liver and spleen via the mononuclear phagocyte system (MPS), and significantly prolonged blood circulation time, as compared to non-surface-modified liposomes, which tend to be rapidly removed from the blood and accumulated in the liver and spleen.

The most commonly used and commercially available PEG-substituted phospholipids are based on phosphatidyl ethanolamine (PE), usually DSPE (distearoyl phosphatidyl ethanolamine), which is negatively charged at the polar head group. Negative surface charge in a liposome can be disadvantageous in some aspects, e.g. in interactions with cells (see, for example, Miller et al., Biochemistry, 37:12875-12883 (1998)), and in the delivery of cationic drugs, where leakage of the drug may occur (see, for example, Webb et al., Biochim. Biophys. Acta, 1372:272-282 (1998)).

Accordingly, it would be beneficial to provide uncharged PEG-derivatized lipids that incorporate efficiently into lipid bilayers and provide long blood circulation times to liposomes. Ideally, such lipids are of low toxicity and easily produced.

Summary of the Invention

In one aspect, the present invention includes a liposomal composition having from about 1 mole percent to about 10 mole percent of a neutral lipopolymer wherein the neutral lipopolymer is represented by the formula:



wherein:

each of R^1 and R^2 is an alkyl or alkenyl chain having between about 8 carbon atoms and about 24 carbon atoms;

n is between about 10 and about 300,

5 Z is selected from the group consisting of hydroxy, alkoxy, benzyloxy, carboxylic ester, sulfonic ester, alkyl or aryl carbonate, amino, and alkylamino; and

L is selected from the group consisting of (i) $-X-(C=O)-Y-CH_2-$, (ii) $-X-(C=O)-$, and (iii) $-X-CH_2-$, where X and Y are independently selected from oxygen, NH, and a direct linkage. Preferably, the composition includes from about
10 3 mole percent to about 6 mole percent of the neutral lipopolymer.

 In another aspect, L is a hydrolyzable linkage such as a carbamate linkage, an ester linkage, or a carbonate linkage. In yet another aspect, Z is hydroxy or methoxy. Preferably, R^1 and R^2 are unbranched. In one aspect, R^1 and R^2 are both stearyl groups ($C_{17}H_{35}$). In another aspect, the value of n is preferably between
15 about 20 and about 115, such that the molecular weight of the PEG group is between about 1000 Da to about 5000 Da.

 The invention also provides a method for increasing blood circulation time of a liposome containing vesicle-forming lipids, by incorporating in the liposome about 1 mole percent to about 10 mole percent of a neutral lipopolymer having the formula
20 as shown above. The invention further provides lipopolymers represented by this formula.

Brief Description of the Drawings

 Figure 1 shows a synthetic scheme for the preparation of a carbamate-linked
25 uncharged lipopolymer, referred to herein as PEG-c-DS;

 Figures 2A-2D show synthetic schemes for the preparation of ether-, ester-, amide-, and keto-linked uncharged lipopolymers;

 Figures 3A-3C are graphs showing the biodistribution of HSPC/Chol liposomes containing 3 mole percent PEG-c-DS (A); 5 mole percent PEG-DSPE (B); or 5 mole
30 percent PEG-c-DS (C), in the blood, liver, and spleen;

Figure 4 is a graph showing the retention in the blood of 2:1 HSPC PEG free liposomes (crosses), i.e., no PEG, 5 mole percent PEG-DSPE (triangles), and 5 mole percent PEG-c-DS (circles); and

Figure 5 is a graph showing the retention in the blood of PHEPC liposomes containing 5 mole percent PEG-c-DS (circles) and 5 mole percent PEG-DSPE (squares).

Detailed Description of the Invention

I. Definitions

As used herein, the term "neutral" lipopolymer refers to a lipopolymer that is uncharged, i.e., having no ionic character.

"Vesicle-forming lipids" refers to amphipathic lipids which have hydrophobic and polar head group moieties. Such vesicle-forming lipids can spontaneously form into bilayer vesicles in water as exemplified by phospholipids, or can be stably incorporated into lipid bilayers, wherein the hydrophobic moiety is in contact with the interior, i.e., one hydrophobic region of the bilayer membrane, and the polar head group moiety is oriented toward the exterior, i.e., the polar surface of the membrane. A class of vesicle-forming lipids of this type typically include one or two hydrophobic acyl hydrocarbon chains or a steroid group, and may contain a chemically reactive group, (such as an amine, acid, ester, aldehyde or alcohol) at the polar head group. Included in this class are the phospholipids, such as phosphatidyl choline (PC), phosphatidyl ethanolamine (PE), phosphatidic acid (PA), phosphatidyl inositol (PI), and sphingomyelin (SM), where the two hydrocarbon chains are typically between from about 14 to about 22 carbon atoms in length, and have varying degrees of unsaturation. Other vesicle-forming lipids include glycolipids, such as cerebrosides and gangliosides, and sterols, such as cholesterol. For the compositions described herein, phospholipids, such as PC and PE, cholesterol, and the neutral lipopolymers described herein are preferred components.

"Alkyl" refers to a fully saturated monovalent radical containing carbon and hydrogen, which may be branched or a straight chain. Examples of alkyl groups are


methyl, ethyl, n-butyl, t-butyl, n-heptyl, and isopropyl. "Lower alkyl" refers to an alkyl radical from about one to about six carbon atoms, as exemplified by methyl, ethyl, n-butyl, i-butyl, t-butyl, isoamyl, n-pentyl, and isopentyl.

"Alkenyl" refers to monovalent radical containing carbon and hydrogen, which may be branched or a straight chain, and contains at least one double bond.

Abbreviations: PEG: polyethylene glycol; mPEG: methoxy-terminated polyethylene glycol; Chol: cholesterol; PC: phosphatidyl choline; PHPC: partially hydrogenated phosphatidyl choline; PHEPC: partially hydrogenated egg phosphatidyl choline; HSPC: hydrogenated soy phosphatidyl choline; DSPE: distearoyl phosphatidyl ethanolamine; DSP or PEG-c-DS: distearoyl (carbamate-linked) PEG; APD: 1-amino-2,3-propanediol; DTPA: diethylenetetramine pentaacetic acid; Bn: benzyl.

II. Neutral Lipopolymers

The PEG-substituted neutral lipopolymers of the invention have the structure shown below:



wherein:

each of R¹ and R² is an alkyl or alkenyl chain having between about 8 to about 24 carbon atoms;

n is between about 10 and about 300,

Z is selected from the group consisting of hydroxy, alkoxy, benzyloxy, carboxylic ester, sulfonic ester, alkyl or aryl carbonate, amino, and alkylamino; and

L is selected from the group consisting of (i) -X-(C=O)-Y-CH₂-, (ii) -X-(C=O)-, and (iii) -X-CH₂-, where X and Y are independently selected from oxygen, NH, and a direct linkage.

The lipopolymers include a neutral linkage (L) in place of the charged phosphate linkage of PEG-phospholipids, such as PEG-DSPE, which are frequently employed in

sterically stabilized liposomes. This neutral linkage is typically selected from a carbamate, an ester, an amide, a carbonate, a urea, an amine, and an ether.

Hydrolyzable or otherwise cleavable linkages, such as carbamates, carbonates, and esters, are preferred in applications where it is desirable to remove the PEG chains after a given circulation time *in vivo*. This feature can be useful in releasing drug or facilitating uptake into cells after the liposome has reached its target (Martin et al., U.S. Patent No. 5,891,468; Zalipsky et al., PCT Publication No. WO 98/18813 (1998)).

The PEG group attached to the linking group preferably has a molecular weight from about 1000 Da to about 15000 Da; that is, where n is between about 20 and about 340. More preferably, the molecular weight is from about 1000 Da to about 12000 Da (n = about 20 to about 275), and most preferably between about 1000 Da to about 5000 Da (n = about 20 to about 115). R^1 and R^2 are typically from about 8 carbon atoms to about 24 carbon atoms, and are preferably between about 16 to about 20 carbons in length. Most preferably, $R^1 = R^2 = C_{17}H_{35}$ such that COOR is a stearyl group.

As stated above, the incorporation of an uncharged lipid into a liposome can present significant advantages, such as reduced leakage of an encapsulated cationic drug. Additionally, another advantage is a greater flexibility in modulating interactions of the liposomal surface with target cells and with the RES (Miller et al., Biochemistry, 37:12875-12883 (1998)). PEG-substituted synthetic ceramides have been used as uncharged components of sterically stabilized liposomes (Webb et al., Biochim. Biophys. Acta, 1372:272-282 (1998)); however, these molecules are complex and expensive to prepare, and they generally do not pack into the phospholipid bilayer as well as diacyl glycerophospholipids.

The lipopolymers can be prepared using standard synthetic methods. For example, the carbamate-linked compound ($L = -O-(C=O)-NH-CH_2-$) is prepared, as shown in Fig. 1, by reacting the terminal hydroxyl of mPEG (methoxy-PEG) with *p*-nitrophenyl chloroformate to yield the *p*-nitrophenyl carbonate. This product is then reacted with 1-amino-2,3-propanediol to yield the intermediate

carbamate. The hydroxyl groups of the diol are acylated to yield the final product. A similar synthesis, using glycerol in place of 1-amino-2,3-propanediol, can be used to produce a carbonate-linked product ($L = -O-(C=O)-O-CH_2-$). Preparation of carbamate-linked distearoyl and diicosanoyl lipopolymers is also described in

5 Example 1.

As shown in Fig. 2A, an ether-linked lipopolymer ($L = -O-CH_2-$) is prepared by reacting the terminal hydroxyl of mPEG-OH with glycidyl chloride, hydrolyzing the resulting epoxide, and acylating the resulting diol. Ester-linked lipopolymers ($L = -O-(C=O)-$ or $-O-(C=O)-CH_2-$) can be prepared, for example, as shown
10 in Fig. 2B, by reacting mPEG-OH with an activated derivative of glyceric acid acetone (2,2-dimethyl-1,3-dioxolane-4-carboxylic acid) or the four-carbon homolog, 2,2-dimethyl-1,3-dioxolane-4-acetic acid. The diol is then deprotected and acylated.

Corresponding reactions using mPEG-NH₂, prepared according to the method
15 described in Zalipsky et al., PCT Publication No. WO 98/18813 (1998), in place of mPEG-OH, may be used to prepare lipopolymers having amide, urea or amine linkages (i.e., where $L = -NH-(C=O)-NH-$, $-NH-(C=O)-CH_2-$, $-NH-(C=O)-NH-CH_2-$, or $-NH-CH_2-$).

Compounds in which L is $-X-(C=O)-$, where X is O or NH, can be prepared
20 by reaction of an activated carboxyl-terminated PEG (prepared by oxidation of hydroxyl-terminated PEG and activation of the carboxyl group by, for example, conversion to the nitrophenyl ester or reaction with DCC) with 1,2,3-propanetriol or 1-amino-2,3-propanediol, respectively (Fig. 2C). A keto-linked compound (i.e. where X is a direct linkage) may be prepared by condensation of aldehyde
25 terminated PEG (prepared by mild oxidation of hydroxyl-terminated PEG) with, for example, the Grignard reagent of 1-bromo-2,3-propanediol acetone (Fig. 2D), followed by oxidation to the ketone, under non-acidic conditions, and hydrolysis of the acetone to the diol. In each case, the diol is then acylated as usual.

The terminus of the PEG oligomer not linked to the glycerol moiety
30 (α terminus; group Z above) is typically hydroxy or methoxy, but may be

functionalized, according to methods known in the art, to facilitate attachment of various molecules to the neutral lipopolymer, and/or for use in targeting the liposomes to a particular cell or tissue type or otherwise facilitating drug delivery. Molecules to be attached may include, for example, proteins, peptides, saccharides, antibodies, or vitamins. Examples 2 and 3 describe steps in the preparation of α -functionalized lipopolymers following routes similar to those described above, but are prepared with commercially available PEG oligomers wherein the α terminus is substituted with a group, such as t-butyl ether or benzyl ether, which is readily converted to hydroxyl after synthesis of the lipid portion of the molecule. This terminus is then activated, in this case, by conversion to a p-nitrophenylcarbonate.

III. Liposome Pharmacokinetics

Long-circulating liposomes are formed by incorporating from about 1 to about 10 mole %, and more preferably from about 3 to about 6 mole %, of a neutral lipopolymer into liposomes composed of vesicle-forming lipids. To illustrate, liposomes incorporating from about 3 to about 5 mole % of either mPEG₂₀₀₀-DSPE (distearoyl phosphatidyl ethanolamine) or carbamate linked lipopolymer, mPEG₂₀₀₀-c-DS were prepared as described in Example 4. The balance of the lipids consisted of HSPC and cholesterol in a 1.5:1 mole ratio. The liposomes were loaded with the marker ¹²⁵I-tyraminylinulin. A sample of each preparation was injected into the tail vein of mice, and the tissue distribution was determined at various time points, as described in Example 4. Levels present in the blood, liver and spleen are presented in Tables 1-3, and shown graphically in Figs. 3A-3C. The data show the pharmacokinetics of the PEG-c-DS-containing liposomes were very similar to those of the liposomes containing PEG-DSPE.

Table 1 : Liposome Distribution in Blood

Time Point	% of Injected Dose		
	A	B	C
30 min	--	94.8 \pm 3.99	89.7 \pm 6.94
2 h	85.1 \pm 1.99	79.8 \pm 3.42	73.0 \pm 17.4
6 h	67.1 \pm 6.25	54.5 \pm 3.05	55.3 \pm 2.51
12 h	54.9 \pm 6.04	39.7 \pm 2.52	44.4 \pm 2.52
24 h	14.8 \pm 2.81	12.4 \pm 2.34	16.6 \pm 2.38

Table 2 : Liposome Distribution in Liver

Time Point	% of Injected Dose		
	A	B	C
30 min	--	2.27 \pm 0.13	3.14 \pm 0.95
2 h	8.76 \pm 2.01	9.42 \pm 1.24	11.7 \pm 1.74
6 h	21.7 \pm 2.55	19.3 \pm 1.37	20.8 \pm 0.86
12 h	26.6 \pm 0.51	26.4 \pm 1.99	30.4 \pm 1.28
24 h	43.9 \pm 2.7	36.6 \pm 2.25	42.6 \pm 0.48

5

Table 3 : Liposome Distribution in Spleen

Time Point	% of Injected Dose		
	A	B	C
30 min	--	0.09 \pm 0.06	0.23 \pm 0.08
2 h	0.96 \pm 0.16	0.99 \pm 0.09	1.08 \pm 0.09
6 h	1.94 \pm 0.07	1.96 \pm 0.29	2.12 \pm 0.13
12 h	3.15 \pm 0.31	3.13 \pm 0.12	3.35 \pm 0.22
24 h	4.69 \pm 0.37	3.91 \pm 0.31	4.56 \pm 0.29

A similar study compared the performance of both PEG lipids against a control
 10 formulation containing no PEG lipid. Figure 4 shows the retention in the blood of
 2:1 HSPC liposomes containing no PEG lipid (crosses), 5 mole % PEG₂₀₀₀-DSPE
 (triangles), or 5 mole % PEG₂₀₀₀-c-DS (circles).

Further studies were performed using liposomes containing mPEG₂₀₀₀-c-DS:
 PHPC: Chol in a 5:55:40 molar ratio. The liposomes were labeled by incorporation

of an indium-DTPA complex. Percent of injected dose was determined in the blood and in various tissues at 24 hours. The results are shown in Tables 4 – 6. Again, the liposomes showed typical long-circulating pharmacokinetics, with an average retention of greater than 70% of the injected dose after 4 hours, and greater than 30% after 24 hours.

Table 4. Percent of Injected Dose of Indium in Blood

Animal #	0.0 hrs	0.5 hrs	1.0 hrs	2.0 hrs	4.0 hrs	24 hrs
Rat 1	103.7	91.2	82.5	73.8	72.0	33.1
Rat 2	97.7	87.7	79.4	78.7	74.4	30.7
Rat 3	95.1	83.1	77.8	68.6	64.4	29.8
Rat 4	91.9	85.4	78.5	75.6	72.6	33.2
Average	97.1	86.8	79.6	74.2	70.9	31.7
Std. Dev.	5.0	3.4	2.1	4.2	4.4	1.7

Table 5. Percent of Injected Dose in Tissues at 24 Hours

Tissue	Rat #1	Rat #2	Rat #3	Rat #4	Average	Std. Dev.
Liver	7.5	6.9	6.7	7.2	7.1	0.3
Spleen	4.9	5.4	5.6	4.8	5.2	0.4
Heart	0.4	0.5	0.5	0.6	0.5	0.1
Kidneys	1.2	1.2	1.0	1.2	1.1	0.1
Lung	0.7	0.7	0.7	0.8	0.7	0.1
Skin	0.1	0.3	0.2	0.2	0.2	0.1
Bone	0.3	0.2	0.2	0.2	0.2	0.2
Muscle	0.1	0.1	0.1	0.2	0.1	0.4
Urine	11.2	13.4	5.7	12.3	10.7	3.4

Table 6. Percent of Injected Dose Per Gram in Tissues at 24 Hours

Tissue	Rat #1	Rat #2	Rat #3	Rat #4	Average	Std. Dev.
Liver	0.7	0.7	0.7	0.7	0.7	0.3
Spleen	7.3	6.9	8.2	5.9	7.1	0.9
Heart	0.5	0.5	0.5	0.5	0.5	0.4
Kidneys	0.6	0.6	0.5	0.6	0.6	0.6
Lung	0.6	0.5	0.5	0.6	0.5	0.6
Skin	0.1	0.1	0.1	0.1	0.1	0.1
Bone	0.4	0.4	0.4	0.4	0.4	0.3
Muscle	0.1	0.1	0.1	0.1	0.1	0.2
Urine*	0.6	0.6	0.3	0.8	0.6	0.2

* Percent of injected dose per mL.

Finally, liposomes containing 5 mole % mPEG₂₀₀₀-c-DS or mPEG₂₀₀₀-DSPE and the remainder PHEPC, were compared with respect to percent remaining in the blood up to 24 hours post administration. As shown in Figure 4, the pharmacokinetics were virtually identical, with approximately 40% retention after 24 hours.

All publications, patents and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.

The following Examples illustrate but are not intended in any way to limit the invention.

Example 1A. Synthesis of mPEG-c-DS (mPEG aminopropanediol distearoyl; α -methoxy- ω -2,3-di(stearoyloxy)propylcarbamate poly(ethylene oxide))

A solution of mPEG₂₀₀₀ (20 g, 10 mol) was azeotropically dried in toluene (50 mL, 120°C). After the temperature of the above solution reached 25°C, it was
 5. treated with nitrophenyl chloroformate (3.015 g, 15 mol) followed by TEA (2.01 mL, 15 mol). This mixture was allowed to react for 1½ hr. The TEA-salt was filtered and the solvent removed to give crude mPEG₂₀₀₀-nitrophenylchloroformate, to which a solution of aminopropanediol (3 g, 30 mol) in acetonitrile (50 mL) was added. This mixture was stirred overnight at room temperature. The insolubles
 10 were removed by filtration and the solvent was evaporated. The product was recrystallized twice from isopropanol. Yield: 13.7 g, 65%. ¹HNMR: (300 MHz, DMSO-D₆) δ 3.23 (s, OCH₃, 3H), 3.65 (s, PEG, 180H), 4.05 (t, urethane CH₂, 2H), 4.42 (t, 1°OH, 1H), 4.57 (d, 2° OH, 1H).

The product, mPEG₂₀₀₀ aminopropanediol (2.3 g, 1.08 mol, 2.17 meq of OH),
 15 was dissolved in toluene (30 mL) and azeotropically dried, removing about 10 mL of the solution. The solution was allowed to cool to room temperature. Pyridine (4 mL, 20%) was added by pipette, followed by addition of stearoyl chloride (1 g, 4.3 mol). Immediately a white precipitate was formed. The reaction mixture was refluxed overnight at 120°C and allowed to cool. When the temperature of the
 20 reaction flask reached about 40°C, the pyridine salt was filtered. The filtrate was evaporated. The product (PEG₂₀₀₀-c-DS) was purified by recrystallizing twice from isopropanol (2 × 30 mL) and dried *in vacuo* over P₂O₅.

Yield: 2.26 g, 80%. TLC (chloroform:methanol, 90:10): mPEG aminopropanediol R_f = 0.266; PEG-c-DS R_f = 0.533. ¹HNMR: (300 MHz,
 25 DMSO-D₆) δ 0.89 (t, CH₃, 6H), 1.26 (s, CH₂, 56 H), 1.50 (2t, 2CH₂, 4H), 2.24 (t, CH₂CH₂ C=O, 4H), 3.23 (s, OCH₃, 3H), 3.50 (s, PEG, 180H), 4.00 (dd, CH₂ of APD, 1H), 4.02 (t, CH₂OC=O-N, 2H), 4.20 (dd, CH₂ of APD, 1H), 4.98 (m, CHOC(O), 1H), 7.34 (m, NH, 1H).

A similar procedure was used to prepare mPEG-c-DS using mPEG polymers of
 30 molecular weight 750, 5000, and 12000. The structures were verified by ¹H-NMR

and mass spectrometry. Molecular weights as determined by MALDI (Matrix Assisted Laser Desorption/Ionization) are given below:

Conjugate	MW by MALDI
mPEG(750)-c-DS	1426
mPEG(2000)-c-DS	2892
mPEG(5000)-c-DS	5816
mPEG(12000)-c-DS	12729

5

Example 1B. Synthesis of PEG-c-DE (mPEG aminopropanediol dieicosanoyl: α -methoxy- ω -2,3-di(ecosanoyloxy)propylcarbamate poly(ethylene oxide))

In a 100 ml round bottom flask, ecosanoic acid (500 mg, 1.6 mmol) was dissolved in toluene (20 ml) and oxalyl chloride (147 μ l, 1.68 mmol) was added by
 10 pipette. To the stirring reaction, 1% DMF was added. Upon addition of DMF, gas was released. All contact with this gas must be avoided. After 10 minutes, the toluene was evaporated, and an additional 20 ml of toluene was added and evaporated to remove any excess of oxalyl chloride. The residue was redissolved in 10 ml of toluene. mPEG-aminopropanediol, prepared as described above, (1.19 g,
 15 0.56 mmol) was added to the solution, a reflux condenser was attached, and the mixture was refluxed overnight. Analysis by TLC (methanol and chloroform, 9:1) showed the reaction to be complete. After the reaction mixture cooled, the undissolved material was filtered, and the filtrate was taken to dryness. The product was purified by recrystallizing three time from isopropanol and dried *in vacuo* over
 20 P₂O₅. Yield: 1.0 mg, 70%. ¹HNMR: (360 MHz, DMSO-D₆) δ 0.89 (t, CH₃, 6H), 1.26 (s, CH₂, 66 H of lipid), 1.50 (t, 2CH₂, 4H), 2.24 (t, CH₂CH₂ C=O, 4H), 3.23 (s, OCH₃, 3H), 3.50 (s, PEG, 180H), 4.00 (dd, CH₂ of APD, 1H), 4.05 (t, CH₂CH₂C+O, 4H), 3.23 (s, OCH₃, 3H), 3.50 (s, PEG, 180H), 4.00 (dd, CH₂ of APD, 1H), 4.05 (t, CH₂OC=O-N, 2H), 4.20 (dd, CH₂ of APD, 1H), 4.98
 25 (m, CHOC(O), 1H), 7.34 (m, NH, 1H) ppm.

Example 2. Preparation of *t*-Bu-O-PEG-Aminopropanediol via *t*-Bu-O-PEG-O-Succinimide

A. *t*-Bu-O-PEG-O-Succinimide

*t*Bu-O-PEG-2000 from Polymer Labs (10 g, 5 mmol) was azeotropically dried
5 by dissolving in 120 mL toluene and removing about 20 mL of the solvent,
collecting any water in a Dean Stark trap.

The solution was cooled to room temperature, and phosgene (15 ml) was added.
The mixture was allowed to react overnight at room temperature. After the
completion of the reaction, the solvent was removed by rotary evaporator. About
10 50 ml of fresh toluene was added and removed by rotary evaporator. The residue
was dissolved in dry toluene (30 ml) and methylene chloride (10 ml). To this
solution, N-hydroxysuccinimide (1.7 g, 14.8 mmol) and triethylamine (2.1 ml, 14.9
mmol) were added, and the mixture was allowed to react overnight at room
temperature, after which time the reaction was complete by TLC.

15

Compound	R _f (CHCl ₃ : CH ₃ OH, 90:10)
<i>t</i> -Bu-O-PEG-OH	0.44
<i>t</i> -Bu-O-PEG-OSc	0.51

The salt was filtered from the reaction mixture, the solvent was removed by
evaporation, and the solid was recrystallized twice from isopropyl alcohol and dried
over P₂O₅. Yield: 9.2, 85%. ¹HNMR: (CDCl₃, 360 MHz) δ 1.25 (s, *t*-Bu, 9H),
20 2.82 (s, CH₂CH₂, 4H), 3.60 (s, PEG, 180 H), 4.45 (t, CH₂OCONH, 2H) ppm.

B. *t*-Bu-O-PEG-Aminopropanediol

To a solution of aminopropanediol (300 mg, 3.2 mmol) in DMF (10 ml), *t*-Bu-PEG-
OSc (5 g, 2.29 mmol) was added and allowed to react overnight. All NHS ester
25 was consumed, giving a mixture showing one spot on TLC.

Compound	R _f (CHCl ₃ : CH ₃ OH, 90:10)
<i>t</i> -Bu-O-PEG-OSc	0.51
<i>t</i> -Bu-O-PEG-APD	0.35

A previously washed acidic ion exchange resin (~ 1 g) was added to the reaction mixture and removed by filtration after 30 minutes. The solvent was removed and the residue recrystallized from 200 mL of isopropyl alcohol. The solid was collected and dried over P₂O₅. Yield: 4.2 g, 85 %. ¹HNMR: (D6-DMSO, 360 MHz) δ 1.25 (s, *t*-Bu, 9H), 3.68 (s, PEG, 180 H), 4.03 (t, CH₂OCONH, 2H), 4.43 (t, 1°OH, 1H), 4.55 (d, 2°OH, 1H), 6.98 (t, NH, 1H) ppm.

10 Example 3. Preparation of *p*-Nitrophenylcarbonate-PEG-c-DS

A. Bn-O-PEG-Nitrophenylcarbonate (NPC)

Bn-O-PEG-2000 from Shearwater Polymers (Huntsville, LA; 5 g, 2.41 mmol) was azeotropically dried by dissolving in 120 mL toluene and removing about 20 mL of the solvent, collecting any water in a Dean Stark trap. The solution was cooled to room temperature and remaining solvent was evaporated under reduced pressure.

The residue was dissolved in 30 ml of methylene chloride/ethyl acetate (60:40), and *p*-nitrophenylchloroformate (729 mg, 3.6 mmol) and triethylamine (1 ml, 7.2 mmol) were added. The reaction was carried out at 4°C for 8-16 hours. This method slows down the reaction but eliminates the formation of bis PEG-carbonate. A UV visible spot on GF silica plate indicated the completion of the reaction.

The reaction mixture was treated with previously cleaned acidic and basic ion exchange resin for 30 minutes, filtered, and taken to complete dryness. The product was recrystallized from isopropyl alcohol and dried over P₂O₅. Yield: 4.4 g, 80%.

25 B. Bn-O-PEG-Aminopropanediol

To a solution of aminopropanediol (260 mg, 1.9 mmol) in DMF (10 ml), Bn-O-PEG-NPC, as prepared above (4.3 g, 2.9 mmol), was added and reacted for 5

hours. All Bn-O-PEG-NPC was consumed, the reaction mixture giving one spot on TLC (chloroform:methanol:water 90:18:2).

The reaction mixture was treated with 5 g previously cleaned acidic ion exchange resin for 30 minutes, filtered, and taken to complete dryness. The product
5 was recrystallized from isopropyl alcohol and dried over P_2O_5 . Yield: 3.8 g, 91%.

C. Bn-O-PEG-c-Distearoyl

A solution of Bn-O-PEG-aminopropanediol (3 g; 1.36 mmol), stearic acid (1.94 g, 6.79 mmol), and DPTS (4-(dimethylamino)pyridinium 4-toluenesulfonate) as catalyst (408 mg, 1.36 mmol) was stirred at room temperature for 20 minutes.
10 Diisopropylcarbodiimide (1.28 ml, 8.16 mmol) was added by pipette and the mixture allowed to react overnight. TLC (chloroform:methanol, 90:10) showed complete reaction of the diol.

Basic ion exchange resin (~ 5g) was added to the reaction mixture. After 30 minutes of shaking, the resin was filtered and the filtrate was taken to dryness. The
15 residue was recrystallized from isopropanol (100 ml) and dried over P_2O_5 . Yield: 4 g, 80%.

D. HO-PEG-c-Distearoyl

Two different approaches were taken for the deprotection of the benzyl group of Bn-O-PEG-c-DS.

20 Method 1. Hydrogenolysis: Deprotection by Palladium on Carbon. To a solution of Bn-O-PEG-c-DS (218 mg, 0.08 mmol) in 5 ml of methanol, 10% Pd/C (110 mg) and ammonium formate (107 mg, 0.8 mmol) were added and the mixture allowed to react at room temperature overnight. Pd/C was removed by filtration over Celite®, and the filtrate was taken to dryness. The residue was dissolved in
25 chloroform and washed three times with saturated NaCl. The chloroform phase was collected, dried with $MgSO_4$, filtered and concentrated. The solid residue was lyophilized from *t*BuOH, and the resulting powder was dried over P_2O_5 . Yield: 80%, 175 mg.

Method 2. Deprotection by Titanium Tetrachloride. A solution of Bn-O-PEG-
30 c-DS (1.18 g, 0.43 mmol) in methylene chloride (10 ml) was cooled in an ice bath

for 5 minutes. Titanium tetrachloride (3 ml, 21.5 mol, excess) was transferred via an oven dried syringe into the sealed reaction flask. After 5 minutes, the ice bath was removed, and the deprotection reaction was carried out overnight at room temperature. Complete deprotection was shown by a lower shifted spot (relative to starting material) on a GF silica TLC plate.

About 40 ml of chloroform was added to the reaction mixture, and the mixture was transferred to a separatory funnel containing 40 ml of saturated NaHCO_3 . The mixture was shaken gently (to avoid formation of an emulsion) and the chloroform layer was collected. This extraction was repeated 3 times, and the chloroform phase was collected and was extracted once more with a fresh portion of saturated NaHCO_3 to ensure complete removal of TiCl_4 . The collected chloroform phase was dried with MgSO_4 , filtered and concentrated.

The above residue was dissolved in 1 ml of chloroform and added to a prepared column of silica gel (200-400 mesh, 60 Å). The polarity of the mobile phase (chloroform) was increased by 2% incremental additions of methanol until the product eluted at 10% methanol/90% chloroform. The product was collected and the solvent removed by rotary evaporator. The solid was lyophilized from *t*BuOH and dried over P_2O_5 . Yield: 70%, 800 mg.

E. *p*-Nitrophenylcarbonate-PEG-c-DS

The reaction flask, stirring bar, syringes and starting material (HO-PEG-c-DS, as prepared above) were meticulously dried before start of the reaction.

To a solution of HO-PEG-c-DS (1.2 g, 0.45 mmol) in 10 ml of methylene chloride/ethyl acetate (60:40), *p*-nitrophenylcarbonate (136 mg, 0.65 mmol) and triethylamine (188 μl , 1.35 mmol) were added. The reaction was carried out at 4°C (to eliminate the formation of bisPEG-carbonate) for 8-16 hours, after which time the reaction was complete by GF silica gel TLC.

Compound	R_f (CHCl_3 : CH_3OH , 90:10)
HO-PEG-c-DS	0.40
NPC-PEG-c-DS	0.54

The reaction mixture was treated for 30 minutes with previously cleaned acidic and basic ion exchange resins and filtered. The filtrate was taken to complete dryness and the residue recrystallized from isopropyl alcohol. The solid was dried over P_2O_5 . Yield: 70%. 1H NMR: (D6-DMSO, 360 MHz) δ 0.86 (t, CH_3 , 6 H), 1.22 (s, DS, 56H), 1.48 (m, $CH_2CH_2(CO)$), 4H), 2.26 (2 xt, CH_2OCONH , 2H), 4.03 & 4.22 (2 xd, CH_2CH of lipid, 2H), 4.97 (M, $CHCH_2$ of lipid), 6.98 (t, NH, 1H), 7.55 %8.32 (2xd, aromatic, 4H) ppm.

Example 4. Preparation and Biodistribution Studies of PEG-DSPE- and PEG-c-DS-Containing Liposomes

Lipid films were formed, by dissolution and removal of solvent, from mixtures of HSPC:Chol:PEG lipid in the following ratios:

A: 58:39:3; PEG lipid = PEG-c-DS

B: 57:38:5; PEG lipid = PEG-DSPE


15 C: 57:38:5; PEG lipid = PEG-c-DS

The films were hydrated in freshly prepared ^{125}I -Tyraminylinulin in 25 mM HEPES containing 140 mM NaCl, pH 7.4, and extruded to form liposomes 100-105 nm in diameter. The liposomes were sterilized by filtration through 0.22 μ m Millipore (Millipore Corporation, Bedford, MA) low protein-binding syringe-end filters.

20 Aliquots were counted to determine the injection counts of ^{125}I . Lipid concentrations were determined by assaying the phosphate content of the liposome preparations, and the liposome preparations were diluted in sterile buffer to a final concentration of 2.5 μ mol/mL. Mice were injected iv via the tail vein with 0.2 mL of the diluted liposomes, so that each mouse received 0.5 μ mol of phospholipid. At the various
25 time points, mice were euthanised by halothane anesthesia followed by cervical dislocation, the blood sampled by cardiac bleeds, and the blood and various organs assayed for ^{125}I counts.

IT IS CLAIMED:

1. A liposomal composition comprising from about 1 mole percent to about 10 mole percent of a neutral lipopolymer having the formula:



wherein:

each of R^1 and R^2 is an alkyl or alkenyl chain having between about 8 to about 24 carbon atoms;

n = about 10 to about 300,

Z is selected from the group consisting of hydroxy, alkoxy, benzyloxy, carboxylic ester, sulfonic ester, alkyl or aryl carbonate, amino, and alkylamino; and

L is selected from the group consisting of (i) $\text{---X---(C=O)---Y---CH}_2\text{---}$, (ii) ---X---(C=O)--- , and (iii) $\text{---X---CH}_2\text{---}$, where X and Y are independently selected from oxygen, NH, and a direct linkage;

and the remainder vesicle-forming lipids.

2. The composition of claim 1, wherein X is oxygen and Y is nitrogen.

3. The composition of claim 1, wherein L is a carbamate linkage, an ester linkage, or a carbonate linkage.

4. The composition of claim 3, wherein L is $\text{---O---(C=O)---N---CH}_2\text{---}$ (a carbamate linkage).

5. The composition of claim 1, wherein Z is hydroxy or methoxy.

6. The composition of claim 1, further comprising about 3 mole percent to about 6 mole percent of the neutral lipopolymer.


7. The composition of claim 1, wherein each of R¹ and R² is an unbranched alkyl or alkenyl chain having between about 8 to about 24 carbon atoms.

8. The composition of claim 6, wherein each of R¹ and R² is C₁₇H₃₅.

9. The composition of claim 1, wherein n is between about 20 and about 115.

10. A method for increasing circulation time of a liposome comprising vesicle-forming lipids, the method comprising:

10 incorporating in the liposome, with the vesicle-forming lipids, about 1 mole percent to about 10 mole percent of a neutral lipopolymer having the formula:



wherein:

each of R¹ and R² is an alkyl or alkenyl chain having between about 8 to about 24 carbon atoms;

n = about 10 to about 300,

Z is selected from the group consisting of hydroxy, alkoxy, benzyloxy, carboxylic ester, sulfonic ester, alkyl or aryl carbonate, amino, and alkylamino; and

L is selected from the group consisting of (i) -X-(C=O)-Y-CH₂-, (ii) -X-(C=O)-, and (iii) -X-CH₂-, where X and Y are independently selected from oxygen, NH, and a direct linkage.

11. The method of claim 10, wherein X is oxygen and Y is nitrogen.

12. The method of claim 10, wherein L is a carbamate linkage, an ester linkage, or a carbonate linkage.

13. The method of claim 12, wherein L is $-O-(C=O)-N-CH_2-$ (a carbamate linkage).

14. The method of claim 10, wherein Z is hydroxy or methoxy.


5

15. The method of claim 10, wherein about 3 mole percent to about 6 mole percent of the neutral lipopolymer is incorporated.

16. The method of claim 10, wherein n is between about 20 and about 115.

10

17. A neutral lipopolymer having the formula:



wherein:

each of R^1 and R^2 is an alkyl or alkenyl chain having between about 8 to about
15 24 carbon atoms;

n = about 10 to about 300,

Z is selected from the group consisting of hydroxy, alkoxy, benzyloxy, carboxylic ester, sulfonic ester, alkyl or aryl carbonate, amino, and alkylamino; and

L is selected from the group consisting of (i) $-X-(C=O)-Y-CH_2-$, (ii) $-X-(C=O)-$, and (iii) $-X-CH_2-$, where X and Y are independently selected from
20 oxygen, NH, and a direct linkage.

18. The lipopolymer of claim 17, wherein X is oxygen and Y is nitrogen.

25 19. The lipopolymer of claim 17, wherein L is a carbamate linkage, an ester linkage, or a carbonate linkage.

20. The lipopolymer of claim 19, wherein L is $-O-(C=O)-N-CH_2-$
(a carbamate linkage).

21. The lipopolymer of claim 17, wherein each of R^1 and R^2 is an unbranched
5 alkyl or alkenyl chain having between about 8 and about 24 carbon atoms.

22. The lipopolymer of claim 21, wherein each of R^1 and R^2 is $C_{17}H_{35}$.

23. The lipopolymer of claim 17, wherein Z is hydroxy or methoxy.

10

24. The lipopolymer of claim 17, wherein n is between about 20 and about 115.

1 / 8




FIG. 1

2 / 8




FIG. 2A




FIG. 2B

3 / 8




FIG. 2C




FIG. 2D

4 / 8




FIG. 3A

5 / 8




FIG. 3B

6 / 8




FIG. 3C

7 / 8




FIG. 4




FIG. 5

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/18949

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C08G65/329 A61K9/127

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C08G A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Interrial, CHEM ABS Data, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 786 387 A (ANDO TAKASHI ET AL) 28 July 1998 (1998-07-28) example 5 claims 1,8,14,15	1,5-7,9, 10, 14-17, 21,23,26
A	US 5 891 468 A (ZALIPSKY SAMUEL ET AL) 6 April 1999 (1999-04-06) cited in the application figure 8 -/-	1-24

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

*** Special categories of cited documents :**

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

31 October 2000

Date of mailing of the international search report

15. 11. 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

O'Sullivan, T

INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/US 00/18949

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 18480 A (NEXSTAR PHARMACEUTICALS INC ;GOLD LARRY (US); JANJIC NEBOJSA (US);) 7 May 1998 (1998-05-07) Compound no. 20 page 48 compound no. 8 page 68	1-24
A	FR 2 694 893 A (OREAL) 25 February 1994 (1994-02-25) claim 1	1-24
A	WO 96 10391 A (UNIV BRITISH COLUMBIA) 11 April 1996 (1996-04-11) claims 1-30	1-24

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/18949

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-24 (ALL IN PART)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 00 18949

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-24 (ALL IN PART)

Present claims 1-24 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of said compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds as disclosed in the present examples. Note in particular with respect to present claims 1, 10 and 14 that the search has been limited to the ester derivatives disclosed in the present examples rather than the ether derivatives as defined in the claims, as no support for the preparation of the ether derivatives can be found in the application as filed.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 00/18949

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5786387 A	28-07-1998	WO 9525764 A	28-09-1995
US 5891468 A	06-04-1999	US 6056973 A	02-05-2000
		AU 715063 B	13-01-2000
		AU 4987897 A	11-05-1998
		BR 9712230 A	25-01-2000
		EP 0932391 A	04-08-1999
		WO 9816202 A	23-04-1998
WO 9818480 A	07-05-1998	US 5859228 A	12-01-1999
		US 6092764 A	25-07-2000
		US 6051698 A	18-04-2000
		AU 4990497 A	22-05-1998
		EP 0957929 A	24-11-1999
FR 2694893 A	25-02-1994	AT 145544 T	15-12-1996
		AU 4434193 A	10-02-1994
		CA 2101760 A	04-02-1994
		DE 69306190 D	09-01-1997
		DE 69306190 T	03-04-1997
		DK 582503 T	24-02-1997
		EP 0582503 A	09-02-1994
		ES 2095015 T	01-02-1997
		FR 2694884 A	25-02-1994
		GR 3022513 T	31-05-1997
		JP 2772751 B	09-07-1998
		JP 6184002 A	05-07-1994
		US 5741518 A	21-04-1998
		US 5866158 A	02-02-1999
		ZA 9305568 A	01-03-1994
WO 9610391 A	11-04-1996	AT 177943 T	15-04-1999
		AU 3559895 A	26-04-1996
		CA 2201120 A	11-04-1996
		DE 69508598 D	29-04-1999
		DE 69508598 T	15-07-1999
		DK 783297 T	11-10-1999
		EP 0783297 A	16-07-1997
		ES 2130651 T	01-07-1999
		JP 10506622 T	30-06-1998
		US 5820873 A	13-10-1998